Dr. reddy's laboratories announces the launch of vigabatrin tablets, usp in the u.s. market

Hyderabad, india & princeton, n.j.--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy along with its subsidiaries together referred to as “dr. reddy's”) today announced the launch of vigabatrin tablets usp, 500 mg, a therapeutic equivalent generic version of sabril® (vigabatrin) tablets, usp, approved by the u.s. food and drug administration (usfda). “we are pleased that this product has been designated as a competitive generic therapy (cgt)
RDY Ratings Summary
RDY Quant Ranking